2015
The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD
Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplantation 2015, 51: 273-276. PMID: 26479982, DOI: 10.1038/bmt.2015.247.Peer-Reviewed Original ResearchConceptsGastrointestinal acute GVHDAcute GVHDGrade IIIAllogeneic stem cell transplantCombination of basiliximabSevere GI GvHDSevere grade IIISteroid-refractory diseaseLong-term survivorsStem cell transplantOverall response rateCurrent retrospective studyChronic GVHDGI GVHDSalvage therapySteroid therapyPrimary diseaseCell transplantMedian timeSignificant morbidityPoor outcomeRetrospective studyGVHDMost deathsNew agents
2006
The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation
Foss FM. The Role of Purine Analogues in Low-Intensity Regimens With Allogeneic Hematopoietic Stem Cell Transplantation. Seminars In Hematology 2006, 43: s35-s43. PMID: 16549113, DOI: 10.1053/j.seminhematol.2005.12.007.Peer-Reviewed Original ResearchConceptsBone marrow transplantationAllogeneic stem cellsAcute GVHDConditioning regimensExtracorporeal photopheresisDendritic cellsAllogeneic hematopoietic stem cell transplantationLeukemia/lymphoma (GVL) effectT-cell-depleted graftsAllogeneic bone marrow transplantationHematopoietic stem cell transplantationDonor/recipient matchingAlternative stem cell sourceDonor dendritic cellsFull donor engraftmentHost dendritic cellsSevere acute GVHDTransplant-associated morbidityTransplant-associated toxicityMyeloablative conditioning regimensSeverity of GVHDT effector cellsT-cell depletionInduction of immunosuppressionStem cell transplantation
2003
Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease
Chan GW, Foss FM, Klein AK, Sprague K, Miller KB. Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 753-759. PMID: 14677114, DOI: 10.1016/j.bbmt.2003.08.002.Peer-Reviewed Original ResearchConceptsAcute GVHDHost diseasePreparative regimenExcess blastsAllogeneic transplantationDisease relapseGrade IIAllogeneic stem cell infusionReduced-intensity allogeneic transplantationReduced-intensity preparative regimenAllogeneic bone marrow transplantationHigh-risk MDS patientsExtensive chronic GVHDReduced-intensity transplantationTransplant-related mortalityFull donor chimerismTreatment-related mortalityStem cell infusionBone marrow transplantationMyelodysplastic syndrome patientsChronic myelomonocytic leukemiaSuccessful donor engraftmentChronic GVHDGVHD prophylaxisLess graftPersistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 170-176. DOI: 10.1016/s1083-8791(03)70006-8.Peer-Reviewed Original ResearchConceptsReduced-intensity preparative regimenHost dendritic cellsReduced-intensity regimenPreparative regimenTotal body irradiationDendritic cellsAcute GVHDChronic GVHDDC chimerismConventional regimenBody irradiationAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAllogeneic stem cell transplantationExtensive chronic GVHDDevelopment of GVHDStem cell transplantationBone marrow transplantationBone marrow transplantExtracorporeal photophoresisHost diseaseMarrow transplantationSignificant morbidityMarrow transplantCell transplantation